目的 探讨阳性激发点推拿联合依托芬那酯凝胶治疗对颈肩背肌筋膜炎的临床疗效。 方法 收集2011年2月－10月确诊为颈肩背肌炎的患者52例，采用随机对照试验,其中26例采用依托芬那酯凝胶加阳性激发点推拿（治疗组），另外26例采用传统推拿进行常规推拿手法治疗（对照组）。对两组患者5次治疗后的疗效率、每次治疗后的疼痛面谱量化评分、7个月后随访疼痛复发率等疗效进行对照分析。 结果 治疗组和对照组经连续治疗5次后，总有效率分别为96.15%和80.77%，差异均有统计学意义（P＜0.05）；疼痛面谱量化评分治疗组在第一次治疗后就较对照组改善明显，差异有统计学意义（P＜0.05）；7个月后随访疼痛复发人数治疗组较对照组少，差异有统计学意义（P＜0.05）。 结论 阳性激发点推拿联合依托芬那酯凝胶治疗方案对改善颈肩背肌筋膜炎引发的颈肩背部疼痛不适等症状优于传统推拿组，值得临床推广运用。
目的 通过观察盐酸氨基葡萄糖、依托芬那酯凝胶治疗颞下颌关节紊乱病（TMD）的临床疗效，探寻治疗老年TMD的有效治疗方法。 方法 对2008年7月－2011年12月收治的 35例老年TMD患者，予口服盐酸氨基葡萄糖胶囊750 mg，2次/d，依托芬那酯凝胶5 cm局部外涂，3～4次/d，治疗时间为6周，并对治疗前、后颞下颌关节疼痛程度和活动度进行临床疗效评价。 结果 经治疗，35例患者颞下颌关节疼痛缓解，关节活动度亦明显改善；依据疗效评定标准，治愈10例，显效16例，好转7例，无效2例，总有效率达94.3%；治疗过程中，4例出现轻度胃胀、恶心等不适，2例出现局部皮肤轻度瘙痒现象，无1例中途退出或失访。 结论 盐酸氨基葡萄糖联合依托芬那酯凝胶治疗老年TMD，能缓解关节症状，改善关节活动度，副作用少，值得临床推广运用。
目的 观察非甾体抗炎药依托芬那酯凝胶联合中枢性肌松药替扎尼定对治疗有潜在胃肠道风险的急性痉挛性颈肩腰痛的疗效和安全性。 方法 2012年3月－5月共诊断急性痉挛性颈肩痛及腰痛患者375例，依据排除标准排除33例，根据分组标准将有潜在胃肠道疾病风险者设为试验组（A组，n=63），明确无胃肠道疾病史者按照年龄、性别和疼痛部位与试验组进行配伍设为阳性对照组（B组，n=63）和安慰剂对照组（C组，n=63），未分组144例不纳入统计。试验组服用替扎尼定2 mg，2次/d，同时外用依托芬那酯凝胶5～10 cm均匀涂抹患处，3次/d；对照组服用替扎尼定2 mg，2次/d，同时口服塞来昔布0.2 g，2次/d；安慰剂对照组服用替扎尼定2 mg，2次/d，同时安慰剂1粒，2次/d。观察药物疗效和不良反应。 结果 A组随访57例，平均起效时间为（2.17 ± 0.99） d，总有效44例（77.2%），胃肠道不良反应2例（3.5%）；B组随访54例，平均起效时间为（1.78 ± 0.96） d，总有效45例（83.3%），胃肠道不良反应发生3例（5.5%）；C组随访55例，平均起效时间（4.10 ± 1.63） d，总有效35例（63.6%），胃肠道不良反应发生2例（3.6%）。 结论 依托芬那酯凝胶和口服非甾体抗炎药疗效和起效时间相当，胃肠道耐受性较好，联合用药效果优于单独使用肌松药。对于有潜在胃肠道风险的痉挛性颈肩腰背痛患者可选择外用非甾体抗炎药联合中枢性肌松药的治疗方案，以获得更好的疗效以及较高耐受性。
目的 临床观察盐酸氨基葡萄糖和依托芬那酯凝胶治疗膝骨关节炎（KOA）的疗效。 方法 2010年6月－2012年2月，将354例KOA患者随机分为盐酸氨基葡萄糖组（A组）、依托芬那酯凝胶组（B组）和盐酸氨基葡萄糖+依托芬那酯凝胶组（C组）。A组为口服盐酸氨基葡萄糖，750 mg/次，2次/d，疗程6周；B组为依托芬那酯凝胶外用，2次/d，6周为1个疗程；C组为在A组的基础上同时加用B组的方法。 结果 C组在改善行走疼痛、夜间静息痛、晨僵方面优于A、B组，A组优于B组，差异有统计学意义（P＜0.05）。总有效率A组为79.65%，B组67.28%，C组89.38%，差异有统计学意义（P＜0.05）。出现不良反应A组3例，B组3例，C组4例，均较轻微，无严重不良事件发生。 结论 盐酸氨基葡萄糖和依托芬那酯凝胶治疗KOA均安全、有效，联合应用时，疗效进一步增强。
目的 评价依托芬那酯凝胶治疗腱鞘炎在超声引导下微创术后肿痛的有效性和安全性。 方法 采用随机、对照的设计，将2011年5月－2012年7月，在四川省人民医院门诊接受腱鞘炎超声引导微创术后的患者157例，分为两组，治疗组（n=81）采用依托芬那酯凝胶外用，对照组（n=76）不使用外用药物。 结果 两组治疗后24 h及3 d的疼痛评分、压痛及关节功能缓解率与治疗前自身比较及组间比较，差别均有统计学意义（P＜0.05），7 d时治疗组临床总有效率为90.12%，对照组为89.47%，组间比较无统计学意义（P＞0.05），治疗组在使用应急药物上明显优于对照组。两组安全性评价比较差异无统计学意义（P＞0.05）。 结论 依托芬那酯凝胶能快速、有效、安全地缓解腱鞘炎超声引导微创术后局部肿胀疼痛的症状。
ObjectiveTo analyze the clinical efficacy of etofenamate gel in patients with chronic trauma of locomotion system. MethodsRandomized parallel-controlled trial was conducted. From September 2011 to March 2012, 120 patients who were diagnosed with chronic trauma of locomotion system were divided into two groups. One was etofenamate gel group (group A), and the other was diclofenac sodium cream group (group B). Treatment course was two weeks. ResultsAfter two weeks of therapy, the effective rate of etofenamate gel was 85.0%, and of diclofenac sodium cream was 83.3%. The difference between etofenamate gel and diclofenac sodium cream had no statistical significance. Two drugs had similar efficacy in treating chronic trauma of locomotion system. Two patients in the etofenamate gel group and three in the diclofenac sodium cream group had very slight adverse reactions. ConclusionEtofenamate gel is effective in patients with chronic trauma of locomotion system, and the efficacy is similar with diclofenac sodium cream. It is particularly suitable for patients with gastrointestinal diseases.
ObjectiveTo observe the efficacy and safety of colchicine combined with etofenamate cream in the treatment of acute gouty arthritis. MethodsA total of 150 patients diagnosed with acute gouty arthritis from June 2013 to July 2014 were equally randomized to receive colchicine alone (group A), colchicine with etofenamate cream (group B) and colchicine with etoricoxib (group C). The assessment on joint pain, tenderness, health quality and clinical efficacy of patients in each group was carried out, and the results were compared before and 7 days after the treatment. ResultsBecause of adverse events, the number of patients who withdrew from group A, B and C was respectively 2, 3 and 7. So the actual number of patients completing the study was 48 for group A, 47 for group B and 43 for group C. The patients' and physicians' assessments of mean change in pain intensity from baseline over days 1-7 were comparable in each group, with no statistical significance between groups (P>0.05). The patients' assessment of response to treatment was the highest in the colchicine with etofenamate cream group, and the differences compared with other two groups were significant (P=0.012 and 0.025, respectively). The physicians' global assessment of response to treatment showed no statistical significance between groups (F=0.021, P=0.908). The joint tenderness was most improved in colchicine with etoricoxib group, and the differences compared with other two groups were significant (P=0.041 and 0.034, respectively). The assessments of health quality were similar between groups. The C-reactive protein and erythrocyte sedimentation rate were decreased at study-end in all groups, but statistically significant differences were only found between group A and C (P<0.05). The incidence rate of adverse events was the highest in colchicine with etoricoxib group and the difference from other two groups was significant (P<0.05). ConclusionColchicine with etofenamate cream is as effective as colchicine with etoricoxib for treating acute gout and may have a better safety and tolerability profile.
ObjectiveTo explore the therapeutic effect of etofenamate gel on omarthritis. MethodsA total of 60 patients with omarthritis (diagnosed by MRI) treated between February 2010 and May 2014 were randomly divided into the treatment group and control group, with 30 patients in each. First, all of the patients underwent the oral medication (to diminish inflammation and relieve pain), physiotherapy, injection, and manual relaxation. Then, the patients in the control group were treated with diclofenac gel, while in the treatment group was treated with etofenamate gel. The usage in both groups was 4 times per day; use externally and waited till desiccation. Improvement of clinical signs and symptoms were observed after 2-week treatment. ResultsAfter 2 weeks of treatment, the total effective rate in both of the two groups were 100%. The efficiency rate of the treatment and control group were 76.7% and 46.7%, respectively, with a significant difference (u=3.491, P < 0.05). ConclusionEtofenamate gel and diclofenac gel are effective on omarthritis; etofenamate gel is more effective, which is worthy of clinical applying.